Discover the Best Treatments and Hospitals for Small Intestine Cancer — Overview, Diagnosis & Treatment Options | MyMedicPlus

Small intestine cancers are rare malignancies, comprising approximately 3% of all gastrointestinal cancers despite the small intestine constituting 75% of the length of the GI tract and 90% of its mucosal surface area. This paradox is explained by rapid epithelial cell turnover, alkaline luminal pH, low bacterial load, and high IgA content. Approximately 11,000 new cases occur per year in the United States. Four principal histological subtypes exist: adenocarcinoma (approximately 35%), carcinoid/neuroendocrine tumour (NET, approximately 35%), primary small bowel lymphoma (approximately 15%), and gastrointestinal stromal tumour (GIST, approximately 10%). Adenocarcinomas predominate in the duodenum and proximal jejunum, NETs in the ileum. Presentation is typically late due to vague symptoms and anatomical inaccessibility, often with Stage III or IV disease at diagnosis. Multidisciplinary management at specialist centres using advanced endoscopic and imaging techniques is essential for optimal outcome.

Risk factors vary substantially by histological subtype. For adenocarcinoma, established risk factors include Crohn's disease (7-to-33-fold increased risk from chronic transmural inflammation), celiac disease (chronic mucosal damage driving lymphoma and adenocarcinoma), Lynch syndrome (MLH1, MSH2, MSH6, PMS2 mutations; lifetime small bowel cancer risk approximately 4%), familial adenomatous polyposis (FAP, particularly duodenal adenocarcinoma with Spigelman classification guiding surveillance), MUTYH-associated polyposis, and Peutz-Jeghers syndrome (STK11 mutations, hamartomatous polyps). Smoking, alcohol, and red processed meat consumption additively increase adenocarcinoma risk. For small bowel NETs, the aetiology is predominantly sporadic, arising from enterochromaffin cells in the ileal mucosa; MEN1 syndrome predisposes to duodenal NETs. H. pylori infection and immunodeficiency are associated with primary small bowel lymphoma. GISTs harbour activating mutations in KIT (exon 9 and 11, ~80%) or PDGFRA (exon 18, ~10%).

Small intestine cancer characteristically presents with insidious, non-specific symptoms leading to significant diagnostic delay of 6 to 12 months or longer. The most common presenting symptoms include intermittent central or periumbilical abdominal pain, progressive unintentional weight loss, nausea and vomiting from partial or complete small bowel obstruction, melena (dark tarry stools), or iron-deficiency anaemia from chronic occult bleeding. Acute small bowel obstruction may be the first presentation of adenocarcinoma or large GISTs. Gross lower gastrointestinal haemorrhage is more common with GISTs, which frequently have central cavitation. Carcinoid syndrome — episodic facial flushing (typically triggered by food, alcohol, or stress), secretory watery diarrhoea, and intermittent wheeze — occurs in patients with ileal NETs harbouring hepatic metastases when serotonin bypasses hepatic degradation and enters the systemic circulation. Carcinoid heart disease (right-sided valvular lesions from serotonin deposits) develops in advanced cases. Abdominal mass is palpable in larger tumours.

Diagnosis requires a combination of advanced imaging and endoscopic techniques. CT enterography (CTE) or MR enterography (MRE) provides superior visualisation of the small bowel mucosa, wall enhancement, and mesenteric involvement compared to standard CT. Capsule endoscopy enables non-invasive mucosal assessment of the entire small bowel but cannot obtain biopsies. Double-balloon enteroscopy (DBE) permits direct visualisation and tissue sampling of the deep small bowel, including tattooing of lesions for surgical localisation. PET/CT using 68Ga-DOTATATE is the preferred staging modality for NETs, being more sensitive than conventional CT for detecting liver, nodal, and bone metastases. Biochemical markers include serum chromogranin A and 24-hour urinary 5-HIAA (5-hydroxyindoleacetic acid) for NETs. For adenocarcinoma, molecular profiling encompasses MSI/MMR status, RAS mutation (KRAS, NRAS), and BRAF V600E, which guide systemic therapy selection. KIT and PDGFRA mutational analysis is essential for GISTs to guide imatinib dosing and predict resistance patterns.

Treatment is guided by histological subtype, stage, and molecular profile. For small bowel adenocarcinoma, surgical resection with en bloc regional lymphadenectomy (aiming for at least 10-12 nodes) is the primary curative treatment. Adjuvant chemotherapy with FOLFOX (oxaliplatin, folinic acid, 5-fluorouracil) is recommended for Stage III (node-positive) disease based on extrapolation from colorectal cancer data, as no dedicated randomised trial exists. Advanced adenocarcinoma is treated with FOLFOX or FOLFIRI regimens; MSI-H/dMMR tumours respond to pembrolizumab. For small bowel NETs, surgical resection of the primary tumour and regional lymph nodes is recommended even for low-volume metastatic disease to prevent bowel obstruction. Somatostatin analogues (octreotide LAR monthly or lanreotide autogel) provide antiproliferative benefit in progressive, well-differentiated G1/G2 NETs (PROMID, CLARINET trials). Peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is approved for SSTR2-positive progressive midgut NETs. GISTs: adjuvant imatinib 400 mg daily for 3 years for high-risk resected tumours; metastatic disease treated with imatinib indefinitely, sunitinib second-line, regorafenib third-line.

Prevention strategies are largely aimed at managing heritable predisposition syndromes and modifiable risk factors. Individuals with Lynch syndrome should undergo upper GI endoscopy including visualisation of the duodenum and proximal jejunum every 3-5 years beginning at age 30-35, as per NCCN guidelines. FAP patients require duodenoscopy every 1-3 years based on Spigelman stage. Coeliac disease patients should maintain strict gluten-free diet to reduce intestinal inflammation and associated malignancy risk. Crohn's disease should be managed with effective anti-inflammatory therapy to achieve mucosal healing and reduce carcinogenesis from chronic injury. Testing and eradication of H. pylori infection in Lynch syndrome patients reduces both gastric and potentially small bowel cancer risk. Smoking cessation and moderation of alcohol intake reduce adenocarcinoma risk. Peutz-Jeghers syndrome carriers should undergo small bowel polypectomy via enteroscopy or surgery when polyps exceed 1-2 cm to prevent obstruction and malignant transformation.

Seek prompt medical evaluation for any of the following symptoms, particularly if persistent beyond 2-4 weeks. Iron-deficiency anaemia in the absence of an obvious bleeding source always warrants small bowel investigation after excluding upper and lower GI causes. Recurrent or progressive abdominal pain, especially postprandial cramping, with intermittent vomiting suggests partial small bowel obstruction and requires imaging. Bright red or dark rectal bleeding not attributable to haemorrhoids or anal conditions should prompt urgent investigation. Unexplained weight loss of more than 5% of body weight over 6 months in an adult requires comprehensive evaluation including small bowel assessment. Episodic flushing, especially facial, accompanied by watery diarrhoea may indicate a carcinoid NET and warrants urgent referral for biochemical testing and imaging. Individuals with known Lynch syndrome, FAP, Peutz-Jeghers syndrome, coeliac disease, or Crohn's disease should adhere to their surveillance endoscopy schedules and report any change in symptom pattern immediately to their gastroenterologist.

Adenocarcinoma 5-year survival: approximately 30-40% overall; Stage I exceeds 80%, Stage IV approximately 5-10%. Well-differentiated NETs with low Ki-67: 5-year survival over 90% even with liver metastasis. High-grade neuroendocrine carcinoma: 5-year survival approximately 15-20%. GIST after resection with adjuvant imatinib: excellent outcomes. Overall prognosis for adenocarcinoma is poor due to late-stage presentation and limited randomised trial data for systemic therapy. The prognosis for Discover the Best Treatments and Hospitals for Small Intestine Cancer varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.